While mushrooms containing the psychoactive compound psilocybin remain illegal in most parts of Europe and the United States, Jamaica's government has never outlawed the hallucinogenic fungus and is now cultivating investors in efforts to build up its psychedelics industry.
Read morePsilocybin for Late-Stage Cancer
CU Cancer Center researchers are collaborating on NCI-funded research to understand the effects of psilocybin on the depression and anxiety that people with cancer can feel.
Read moreHow Psilocybin May Rewire the Brain
“One of the most interesting things we’ve learned about the classic psychedelics is that they have a dramatic effect on the way brain systems synchronize, or move and groove together,” said Matthew Johnson, a professor in psychedelics and consciousness at Johns Hopkins Medicine.
“When someone’s on psilocybin, we see an overall increase in connectivity between areas of the brain that don’t normally communicate well,” Johnson said. “You also see the opposite of that – local networks in the brain that normally interact with each other quite a bit suddenly communicate less.”
Read moreMore Psilocybin Research
A recent follow-up study by Johns Hopkins Medicine researchers found two doses of the hallucinogenic compound coupled with psychotherapy resulted in large decreases in major depressive disorder symptoms for most of the study’s participants.
New research is hinting at how the hallucinogenic compound may facilitate reduced depression symptoms.
Read morePsilocybin Microdosing -New Research
Psilocybin for Depression Is Effective for One Year
New research shows that psilocybin treatment for major depression is effective for up to a year for most patients.
Read moreSSRI Drugs and Psilocybin
A new study suggests that SSRI drugs can be used safely with psilocybin to treat depression. Keep reading to learn more.
Read moreMushrooms Instead of Prozac?
Newsweek says: Magic Mushrooms May Be the Biggest Advance in Treating Depression Since Prozac
Read moreMore on Psilocybin Therapy
Psilocybin, Depression and Cancer
COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed the topline data shared today from an open-label study of psilocybin therapy for depression in cancer patients.
Within one week of a single administration of COMP360 psilocybin therapy, 50% of participants achieved remission in depression symptoms, which was sustained for the eight week follow-up period.
Read moreMore Research on Mushrooms
This article proclaims that magic mushrooms may be the biggest advance in treating depression since Prozac. The research continues to impress!
Read more